CJC-1295 in Washington — GHRH Analog Research Guide
CJC-1295 research guide for Washington. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Washington looking to source CJC-1295, the foundational reality is that this compound moves through online research channels. What this means for Washington researchers is that your location matters far less than your ability to verify analytical documentation — and those quality checks are accessible to anyone. A properly operating CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. Use this guide to evaluate CJC-1295 vendors rigorously — the standards covered in this guide are universal across all research contexts.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Washington comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Evaluating CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that lack endotoxin data. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Washington
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that makes anomalous results interpretable.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
